JP4721630B2 - Anti-endotoxin agent and composition for oral cavity containing periodontal disease containing the same - Google Patents

Description

  The present invention inhibits the activity of LPS and is effective for the prevention or treatment of periodontal disease, as well as an anti-endotoxin agent effective for the prevention or treatment of endotoxin shock symptoms due to bacterial infection, and periodontium containing the same. The present invention relates to an oral inhibitor for disease control.

  Endotoxin (endotoxin) is known as one of the components constituting the outer membrane of Gram-negative bacteria. Endotoxin is a kind of lipopolysaccharide (LPS), and its chemical structure consists of a part composed of a polysaccharide and a lipid part (usually called lipid A). When endotoxin is present in the extracellular membrane of the cell, the lipid A portion, which is the hydrophobic portion of endotoxin, is embedded in the lipid bilayer membrane of the extracellular membrane, and the hydrophilic portion of endotoxin The polysaccharide part which exists is present in a protruding form outside the cell. The biological activity of endotoxin is carried by the lipid A portion, and its activity is very diverse. On the other hand, it has an immunostimulatory effect and has a positive effect on the living body, but it also has adverse effects such as causing shock symptoms. I also have.

Also in the field of dentistry, the action of endotoxin has been taken up as a problem, particularly regarding the treatment of periodontal disease. Periodontal disease is seen as an infection caused by bacteria (especially gram-negative anaerobic bacteria) and is considered a major cause of tooth loss. Endotoxin is released from the extracellular membrane of periodontopathic bacteria and acts on living cells such as gingival fibroblasts, and expresses various cytokines, affecting gingival inflammation and alveolar bone resorption. It is believed that. Furthermore, endotoxins are also involved in the process of periodontal tissue regeneration. Normally, endotoxin is easily adsorbed on the tooth surface, and its removal can be dealt with only by physical removal such as scaling and curettage. However, it is considered that such physical removal alone is difficult to remove completely, and the influence of the remaining endotoxin in the periodontal tissue regeneration process is discussed. As for chemical removal, a system using tauroline (see Patent Document 1) has been reported, and its toxicity neutralizing action has been explained. Thus, endotoxins released by gram-negative bacteria are toxic in both medical and dental fields, causing therapeutic problems.
JP-A-5-201878

  An object of the present invention is to provide an anti-endotoxin agent effective for the prevention or treatment of periodontal disease and endotoxin shock caused by LPS, and an oral inhibitor for periodontal disease suppression containing the same.

  As a result of intensive studies in view of the above-mentioned problems of the prior art, the present inventors have found that a surfactant having an amide structure in the molecule inhibits the activity of LPS, preventing or treating periodontal disease, endotoxin shock, etc. Found to be effective. In addition, the present inventor has reported that the cationic surfactant is a fatty acid monoethanolamide, a fatty acid diethanolamide, a fatty acid amide betaine, a fatty acid amide propyl betaine, an N-acyl amino acid salt, an N-coconut oil fatty acid acyl L-arginine ethyl dl- It was found that the anti-endotoxin action of pyrrolidone carboxylate was enhanced. Further, the present inventor is that eugenol, transdermal aldehyde, anethole, and dabana are fatty acid monoethanolamide, fatty acid diethanolamide, fatty acid amide betaine, fatty acid amide propyl betaine, N-acyl amino acid salt, N-coconut oil fatty acid acyl L-arginine It has been found that the bitterness of ethyl dl-pyrrolidonecarboxylate is reduced.

  Based on these findings, the present invention provides the following anti-endotoxin agent and oral cavity composition for periodontal disease suppression.

  Item 1. An anti-endotoxin agent comprising a surfactant having an amide structure in the molecule as an active ingredient.

  Item 2. The surfactant is selected from the group consisting of fatty acid monoethanolamide, fatty acid diethanolamide, fatty acid amide betaine, fatty acid amide propyl betaine, N-acyl amino acid salt and N-coconut oil fatty acid acyl L-arginine ethyl dl-pyrrolidone carboxylate The anti-endotoxin agent according to claim 1, which is at least one kind.

  Item 3. Item 3. The anti-endotoxin agent according to Item 2, wherein the fatty acid-derived acyl group moiety of the surfactant has 8 to 16 carbon atoms.

  Item 4. Item 3. The anti-endotoxin agent according to Item 2, wherein the fatty acid-derived acyl group moiety of the surfactant has 12 to 16 carbon atoms.

  Item 5. The surfactant is a group consisting of coconut oil fatty acid monoethanolamide, coconut oil fatty acid diethanolamide, coconut oil fatty acid amide betaine, coconut oil fatty acid amide propylbetaine and N-coconut oil fatty acid acyl L-arginine ethyl dl-pyrrolidone carboxylate The anti-endotoxin agent according to claim 1, which is at least one selected from the group consisting of:

  Item 6. Item 6. A composition for oral cavity for periodontal disease suppression containing an effective amount of the anti-endotoxin agent according to any one of Items 1 to 5.

  Item 7. Item 7. The oral cavity composition for inhibiting periodontal disease according to Item 6, further comprising at least one cationic surfactant.

  Item 8. Item 8. The oral cavity composition for inhibiting periodontal disease according to Item 7, wherein the cationic surfactant is cetylpyridinium chloride.

  Item 9. The oral cavity composition for periodontal disease suppression in any one of claim | item 6 -8 which further contains the at least 1 sort (s) of compound selected from the group which consists of eugenol, cinnamaldehyde, anethole, and Davana.

  The anti-endotoxin agent of the present invention contains a surfactant having an amide structure in the molecule as an active ingredient. Here, the amide structure means a partial structure represented by the following chemical formula (1).

分子内にアミド構造を有する界面活性剤としては、脂肪酸モノエタノールアミド、脂肪酸ジエタノールアミド、脂肪酸アミドベタイン、脂肪酸アミドプロピルベタイン、Ｎ−アシルアミノ酸塩、Ｎ−ヤシ油脂肪酸アシルL-アルギニンエチルdl−ピロリドンカルボン酸塩などが挙げられ、これらの中の１種又は２種以上を組み合わせて用いられる。

Surfactants having an amide structure in the molecule include fatty acid monoethanolamide, fatty acid diethanolamide, fatty acid amide betaine, fatty acid amide propyl betaine, N-acyl amino acid salt, N-coconut oil fatty acid acyl L-arginine ethyl dl-pyrrolidone A carboxylate etc. are mentioned, Among these, it uses in combination of 1 type, or 2 or more types.

  Fatty acid monoethanolamide, fatty acid diethanolamide, fatty acid amide betaine, fatty acid amidopropyl betaine, N-acyl amino acid salt (if it has a fatty acid moiety), N-coconut oil fatty acid acyl L-arginine ethyl dl-pyrrolidone carboxylate 8-16 are preferable and, as for carbon number of the acyl group part derived from a fatty acid, 12-16 are more preferable. As the fatty acid amide constituting the fatty acid monoethanolamide, fatty acid diethanolamide, fatty acid amide betaine, N-coconut oil fatty acid acyl L-arginine ethyl dl-pyrrolidone carboxylate, the following fatty acid amides or mixtures thereof are preferred. For example, coconut oil fatty acid, octanoic acid (caprylic acid), nonanoic acid, decanoic acid (capric acid), undecanoic acid, dodecanoic acid (lauric acid), tridecanoic acid, tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitin) Acid), oleic acid and the like. Among these, caprylic acid, capric acid, lauric acid, myristic acid, and palmitic acid are preferable, and lauric acid, myristic acid, and palmitic acid are more preferable.

  The carbon number of the acyl group portion derived from the fatty acid is the total number of carbons of the alkyl group constituting the fatty acid and carbons of the carbonyl group constituting the fatty acid. Therefore, fatty acid monoethanolamide having 12 carbon atoms in the fatty acid portion means lauric acid monoethanolamide, and fatty acid amide betaine having 14 fatty acid portions in the fatty acid portion means myristic acid amide betaine.

  Examples of N-acyl amino acid salts include N-acyl-N-methyl-β-alanine salts, N-acyl glutamates, N-acyl-N-methyl taurine salts, N-acyl sarcosine salts, and the like. . As the salt, Na salt, K salt, Mg salt and the like are preferable, and Na salt is more preferable. As the Na salt, for example, sodium N-acyl-N-methyl-β-alanine, sodium N-acylglutamate, sodium N-acyl-N-methyltaurine, sodium N-acylsarcosine, etc. are used.

  These surfactants can be used orally as they are as anti-endotoxins, but they should be used as a pharmaceutical composition for oral administration or a composition for parenteral administration in combination with a pharmaceutically acceptable carrier. Is also possible.

  Pharmaceutical compositions for oral administration can be formulated as known dosage forms such as tablets, pills, granules, fine granules, powders, capsules, solutions, emulsions, suspensions, syrups and the like. These preparations can be produced by a known method. Moreover, in formulating, a suitable carrier etc. can be selected according to a dosage form, and this can be mix | blended.

  For solid preparations, known excipients (anhydrous silicic acid, synthetic aluminum silicate, lactose, corn starch, crystalline cellulose, etc.), binders (carboxymethylcellulose, polyvinylpyrrolidone, etc.), lubricants (magnesium stearate, talc, etc.) Etc.), disintegrating agents (starch, carboxymethylcellulose calcium, etc.), coloring agents, sweetening agents, corrigents and the like.

  In the case of a liquid preparation, it can be an aqueous or oily suspension, solution or syrup. It is also possible to obtain a dry product that can be re-dissolved in an appropriate vehicle. In addition to these, emulsifiers (lecithin, sorbitan monooleate, etc.), emulsification aids (sorbite syrup, methylcellulose, gelatin, etc.), non-aqueous vehicles (coconut oil, peanut oil, etc.), antioxidants, colorants, flavoring agents, etc. Can be blended.

  Pharmaceutical compositions for parenteral administration can be formulated as known dosage forms such as injections, intramuscular injections, infusions, ointments, gels, and suppositories. These preparations can be produced by a known method. For example, in the case of an injection, it can be produced by dissolving, suspending or emulsifying the active ingredient in a sterile aqueous or oily liquid. Moreover, in formulating, a suitable carrier etc. can be selected according to a dosage form, and this can be mix | blended. For example, as an aqueous solution for injection, isotonic solutions containing physiological saline, glucose, and other auxiliary liquids may be mentioned, and an appropriate suspending agent such as sodium carboxymethyl cellulose may be used in combination as necessary. Is possible.

  The dosage of the surfactant having an amide structure in the molecule is appropriately selected according to the administration route, the frequency of administration, the age, body weight and sex of the recipient, and is usually 10 μg to 10 mg per day for adults, preferably Is 0.1 mg to 1 mg.

  The composition for oral cavity control for periodontal disease of the present invention is a composition for oral cavity such as pharmaceuticals and foods, and includes a composition intended for suppression of periodontal disease. For example, it can be used as a toothpaste, powder toothpaste, liquid toothpaste, gel toothpaste, mouthwash, prophy paste, pasta, drop, chewing gum, tablet, mouthwash, oral ointment, etc. Can do. Among these forms, toothpaste, liquid toothpaste, mouthwash, and chewing gum are preferable, and toothpaste, liquid toothpaste, and mouthwash are most preferable.

  The amount of the surfactant having an amide structure in the molecule to be blended in the oral composition is about 0.01 to 1% by weight, preferably about 0.01 to 0.1% by weight, based on the total weight of the composition. is there.

  When preparing these compositions for oral cavity, it is possible to mix commonly used components depending on the form, and the blending amount of these components can be appropriately selected within a range that does not hinder the effects of the present invention. is there. For example, in the case of a dentifrice (toothpaste, liquid dentifrice, powder dentifrice), a polishing agent, an excipient, a foaming agent, a binder, a pH adjuster, a surfactant other than the surfactant which is an active ingredient of the present invention, Wetting agents, sweeteners, fragrances, preservatives, coloring agents, other active ingredients, and the like can be blended.

  As abrasives, dicalcium phosphate dihydrate and anhydrous, calcium phosphate, tricalcium phosphate, calcium carbonate, calcium pyrophosphate, aluminum hydroxide, alumina, silica gel, aluminum silicate, precipitated silica, insoluble sodium metaphosphate Tertiary magnesium phosphate, magnesium carbonate, calcium sulfate, polymethyl methacrylate, bentonite, zirconium silicate, hydroxyapatite, synthetic resin, and combinations thereof are preferably used. The blending amount of the abrasive is usually about 5 to 90% by weight and about 5 to 50% by weight in the case of toothpaste with respect to the total weight of the oral composition.

  Examples of excipients include igneous silica, thickened silica (generally silica having an RDA value of about 30 or less. The RDA value is an abbreviation for Radioactive Dentin Abrasion, for example, the method of Hefferen et al. (J. Dent. Res., Vol. 55, No. 4, 563-573, 1976)), powdered cellulose containing crystalline cellulose, and combinations thereof may be exemplified. it can. Of these, ignitable silica and thickened silica are preferred. The blending amount of the excipient is usually about 0.1 to 30% by weight, preferably about 0.5 to 10% by weight, based on the total weight of the composition.

  Examples of the foaming agent include an anionic surfactant other than the surfactant which is an active ingredient. For example, higher alkyl sulfate salts having 8 to 18 carbon atoms in the alkyl group such as sodium lauryl sulfate and sodium myristyl sulfate; anions such as α-olefin sulfonate salt, higher fatty acid sodium monoglyceride monosulfate, and α-olefin sodium sulfonate Examples thereof include a surfactant and a combination thereof. The amount of these anionic surfactants is usually about 0.001 to 5% by weight, preferably about 0.01 to 2% by weight, based on the total weight of the composition.

  In addition to the anionic surfactants described above, the composition of the present invention, except for surfactants that are active ingredients, includes nonionic surfactants, amphoteric surfactants and the like that are commonly used in oral compositions. A cationic surfactant may be added. Examples of such surfactants include polyoxyethylene fatty acid esters such as polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monolaurate, polyoxyethylene hydrogenated castor oil, polyoxyethylene higher alcohol ethers, polyoxyethylene Polyoxypropylene copolymer, polyoxyethylene polyoxypropylene fatty acid ester alkyl glycoside (for example, alkyl chain: about C8 to C16), polyglycerin fatty acid ester (for example, carbon number of fatty acid portion is about 8 to 16), sucrose fatty acid ester Nonionic surfactants such as (for example, about 8 to 16 carbon atoms in the fatty acid moiety); N-alkyldiaminoethylglycine, alkylbetaine, alkylsulfobetaine, alkylbetaine, imidazoliumbetaine Examples of amphoteric surfactants include cationic surfactants such as alkyltrimethylammonium chloride, alkyltrimethylammonium bromide, alkyldimethylammonium chloride, and cetylpyridinium chloride. These may be used alone or in combination of two or more. be able to. Among these, cationic surfactants (especially cetylpyridinium chloride) that enhance the anti-endotoxin action of surfactants with an amide structure in the molecule and the stability of surfactants with an amide structure in the molecule Polyoxyethylene hydrogenated castor oil and alkyl glycoside that can contribute to improvement are preferred. The amount of these nonionic surfactants, amphoteric surfactants and cationic surfactants is usually about 0.001 to 5% by weight, preferably 0.01 to 2% by weight based on the total weight of the composition. %.

  Binders include cellulose derivatives such as sodium carboxymethyl cellulose; alkali metal alginates such as sodium alginate; gums such as propylene glycol alginate, xanthan gum, tragacanth gum, caraya gum, gum arabic and carrageenan; polyvinyl alcohol, sodium polyacrylate, Examples thereof include synthetic binders such as carboxyvinyl polymer and polyvinylpyrrolidone. A binder may be used independently or may use 2 or more types together. The compounding amount of the binder is usually about 0.3 to 5% by weight with respect to the total weight of the composition.

  As perfumes, eugenol, cinnamic aldehyde, anethole, dabana, anethole, menthol, carvone, vanillin, benzyl succinate, methyl salicylate, limonene, ocimene, n-decyl alcohol, citronellol, α-terpineol, methyl acetate, citronellyl acetate, Examples include methyl eugenol, shioner, linalool, ethyl linalool, crocodile and thymol. These may be used as single product compounds, but may be blended as plant extracts such as essential oils containing them (for example, plant extracts as described below). As perfumes, thyme oil, nutmeg oil, spearmint oil, peppermint oil, fennel oil, lemon oil, orange oil, sage oil, rosemary oil, pimento oil, diatom oil, perilla oil, winter green oil, eucalyptus oil, Examples include plant extracts such as basil oil, tea tree oil, tabana oil, vanilla oil, cranberry oil. A fragrance | flavor may be used independently or may use 2 or more types together. Among these, eugenol, cinnamaldehyde, anethole, and dabana, which are excellent in taste-masking of the surfactant that is the active ingredient of the present invention, are preferable. The blending amount of the fragrance can be appropriately set according to the kind of the fragrance, but is usually about 0.05 to 10% by weight, preferably about 0.1 to 5% by weight, based on the total weight of the composition. is there.

  Examples of the sweetener include saccharin, saccharin sodium, stevioside, acesulfame K, glycyrrhizin, perilartin, thaumatin, aspartylphenylalanine methyl ester, xylitol, palatinose, palatinit, erythritol, maltitol and the like. Sweetening agents may be used alone or in combination of two or more. The blending amount of the sweetener can be appropriately set according to the desired sweetness, but is usually 0.01 to 5% by weight with respect to the total weight of the composition.

  Examples of the wetting agent include sorbite liquid, glycerin, ethylene glycol, propylene glycol, 1,3-butylene glycol, polyethylene glycol, polypropylene glycol, lactit and the like. A wetting agent may be used independently or may use 2 or more types together. The blending amount of the wetting agent is usually about 5 to 70% by weight with respect to the total weight of the composition.

  Examples of the pH adjuster include phosphoric acid and salts thereof (sodium phosphate, sodium hydrogen phosphate, etc.), citric acid and salts thereof (sodium, etc.), phosphoric acid and salts thereof, malic acid and salts thereof, gluconic acid and Salts thereof, maleic acid and salts thereof, aspartic acid and salts thereof, gluconic acid and salts thereof, succinic acid and salts thereof, glucuronic acid and salts thereof, fumaric acid and salts thereof, glutamic acid and salts thereof, adipic acid and salts thereof, Examples include hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium silicate, and the like. A pH adjuster may be used independently or may use 2 or more types together. The blending amount of the pH adjuster is not particularly limited as long as a desired pH is obtained, but is usually about 0.01 to 5% by weight, preferably about 0.1 to 3% by weight, based on the entire composition. The pH of the composition of the present invention is not particularly limited as long as the effect of the present invention is exerted, but is usually about 4 to 10, and preferably about 5.5 to 9.

  Examples of preservatives include benzoates such as sodium benzoate; parabens such as methylparaben and butylparaben. A preservative may be used independently or may use 2 or more types together. The compounding amount of the preservative is usually about 0.01 to 3% by weight with respect to the whole composition.

  Examples of the colorant include legal dyes such as Blue No. 1, Yellow No. 4, Red No. 202, and Green No. 3; mineral dyes such as ultramarine blue, enhanced ultramarine blue, and bitumen; and titanium oxide. A colorant may be used independently or may use 2 or more types together. The blending amount of the colorant is usually about 0.0001 to 1% by weight with respect to the whole composition.

Other active ingredients include, for example, benzethonium chloride, distearyldimethylammonium chloride, stearyldimethylbenzylammonium chloride, stearyltrimethylammonium chloride, lauryltrimethylammonium chloride, quaternary ammonium salts such as laurylpyridinium chloride, chlorhexidine hydrochloride, chlorhexidine acetate , Cationic fungicides such as biguanide fungicides such as chlorhexidine gluconate, alexidine hydrochloride, alexidine acetate and alexidine gluconate; anionic fungicides such as sodium n-lauroyl sarcosine; nonionic such as triclosan and isopropylmethylphenol Disinfectant; dextranase, amylase, papain, protease, mutanase, lysozyme, lytic enzyme (lytech enzyme) Which enzymes; zinc compounds such as zinc oxide and zinc chloride; alkali metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate; fluorides such as sodium fluoride and stannous fluoride; tranexamic acid and epsilon Examples include vitamin E derivatives such as aminocaproic acid, aluminum chlorohydroxyl allantoin, dihydrocholesterol, tocopherol acetate, glycyrrhizin salts, glycyrrhetinic acid, glycerophosphate, chlorophyll, potassium nitrate, sodium chloride, caropeptide, and water-soluble inorganic phosphate compounds. As a water-soluble inorganic phosphate compound,
General formula (2):
M _{m + 2} P _m O _{3m + 1}
[Wherein M represents Na or K, and m is an integer of 2 or more. ]
General formula (3):
(MPO ₃ ) _l
[Wherein M represents Na or K, and l is an integer of 3 or more. ]
The compound represented by these is illustrated.

  m is an integer of usually 2 or more, preferably an integer of about 2 to 6. l is usually an integer of 3 or more, preferably an integer of about 3-6.

  Specific examples of the compound represented by the formula (2) include sodium pyrophosphate, potassium pyrophosphate, sodium tripolyphosphate and the like.

Specific examples of the compound represented by the formula (3) include sodium tetrametaphosphate and sodium hexametaphosphate.
These active ingredients may be used alone or in combination of two or more. The blending amount of the active ingredient is not particularly limited as long as the desired effect is obtained, and can be appropriately set according to the type of the active ingredient. The amount of the active ingredient is usually about 0.001 to 30% by weight, preferably about 0.01 to 20% by weight, based on the total weight of the composition.

  The blending amount of water can be appropriately set according to the dosage form and the like, but is usually about 0 to 97% by weight, preferably about 10 to 50% by weight with respect to the total weight of the composition. Although the compounding quantity of a lower alcohol can be suitably set according to a dosage form etc., it is about 0-20 weight% normally with respect to the composition total weight, Preferably it is about 0-10 weight%. The blending amount of the higher alcohol can be appropriately set according to the dosage form and the like, but is usually about 0 to 50% by weight, preferably about 0 to 30% by weight with respect to the total weight of the composition.

  The anti-endotoxin agent and the composition for oral cavity for periodontal disease suppression of the present invention are effective for the prevention or treatment of periodontal disease and the prevention or treatment of endotoxin shock. Further, by adding a cationic surfactant, fatty acid monoethanolamide, fatty acid diethanolamide, fatty acid amide betaine, fatty acid amide propyl betaine, N-acyl amino acid salt, N-coconut oil fatty acid acyl L-arginine ethyl dl-pyrrolidone A composition effective for preventing or treating periodontal disease or endotoxin shock, in which the anti-endotoxin action of carboxylate is enhanced, can be provided. In addition, the combination of eugenol, transdermal aldehyde, anethole, and dabana helps prevent or treat periodontal disease or endotoxin shock with reduced bitterness of fatty acid monoethanolamide, fatty acid diethanolamide, fatty acid amide betaine, and fatty acid amide propyl betaine. An effective composition can be provided.

  EXAMPLES Hereinafter, although this invention is demonstrated using an Example, this invention is not limited to the following Example.

Example 1: Endotoxin activity inhibitory effect on E. coli LPS Endotoxin activity inhibition test was performed using various test substances. The test was performed by a kinetic colorimetric method using a microplate using Toxicolor LS-6 set manufactured by Seikagaku Corporation. Endotoxin is based on an enzyme reaction that activates a blood cell extract component LAL (Limulus Amebocyte Lysate) of horseshoe crab and causes gelation, and is a method of measuring a degradation product generated by hydrolysis of a synthetic substrate by the enzyme by color development.

  E. coli LPS (Seikagaku Corporation) was dissolved in LPS-free water to prepare a 78.6 pg / ml LPS dilution. The test substance was diluted with LPS-free water to prepare a test substance dilution solution of 100 μg / ml. 25 μL of LPS dilution and 25 μL of test substance dilution were dispensed into each well of the microplate to obtain a test solution. In addition to these, 25 μl of LPS diluent and 25 μl of LPS-free distilled water were dispensed into the wells as controls. Next, 50 μL of LAL reagent was dispensed into each well, stirred for 1 minute, the initial absorbance (405 nm) of the stirred solution was measured, reacted at 37 ° C. for 30 minutes, and then the absorbance (405 nm) of the reaction solution was again measured. The absorbance was measured to determine the rate of change with time (mAbs / min). The inhibition rate was calculated based on the following formula. The inhibition rate is shown in Table 1.

なお、ヤシ油脂肪酸アミドプロピルベタインは炭素数の異なる脂肪酸アミドプロピルベタイン（カプリル酸アミドプロピルベタイン、カプリン酸アミドプロピルベタイン、ラウリン酸アミドプロピルベタイン、ミリスチン酸アミドプロピルベタイン、ヘキサデカン酸アミドプロピルベタイン）の混合物を主成分とする界面活性剤である。

Palm oil fatty acid amide propyl betaine is a mixture of fatty acid amide propyl betaines having different carbon numbers (caprylic acid amide propyl betaine, capric acid amide propyl betaine, lauric acid amide propyl betaine, myristic acid amidopropyl betaine, hexadecanoic acid amidopropyl betaine). Is a surface active agent.

Example 2: Endotoxin activity inhibitory effect of palm oil fatty acid amidopropyl betaine on periodontal disease bacteria and E. coli LPS In addition to E. coli LPS, periodontal disease bacteria (Porphyromonas gingivalis 381) LPS was used, and palm oil fatty acid was used as a test substance. The test was performed in the same manner as in Example 1 except that amidopropyl betaine was used, and a periodontal disease bacteria and E. coli endotoxin activity suppression test was performed. The measurement results are shown in Table 2. Palm oil fatty acid amidopropyl betaine significantly inhibited LPS activity of periodontal disease bacteria.

  The periodontal disease bacteria LPS was produced by the following method.

  Inoculate Porphyromonas gingivalis 381 strain into Trypticase soy broth (yeast extract (1 mg / mL), vitamin K1 (1 mg / L), hemin (5 mg / L) added) medium 20 mL, 37 Anaerobic culture was carried out at 24 ° C. for 24 hours. The above-mentioned trypticase soy broth medium (2 L) was prepared, and the anaerobic culture medium was added to the 2 L medium, followed by anaerobic culture at 37 ° C. for 48 hours. The culture solution was centrifuged (7000 rpm, 10 minutes, 4 ° C.) to obtain bacterial cells. LPS-free water was added to the cells and centrifuged (7000 rpm, 10 minutes, 4 ° C.) to wash the cells. After weighing the wet cell weight of the obtained microbial cells, 40 mL of LPS-free water was added per 10 g of microbial cells to obtain a microbial suspension, which was heated in a thermostatic bath at 65 to 68 ° C. 40 mL of 90% phenol was added to the heated bacterial suspension, and the mixture was vigorously shaken for 15 minutes while heating to 65 to 68 ° C., and allowed to stand for 1 hour under ice cooling. After standing, it was centrifuged (4000 rpm, 15 minutes, 4 ° C.) to obtain an aqueous layer. Furthermore, 40 mL of LPS-free water was added to the phenol layer, and the same operation was repeated twice. The collected aqueous layer was put into a dialysis membrane (Speotra / Por. MWCO: 6000-8000) and dialyzed against sterile distilled water at 4 ° C. overnight. The dialyzed aqueous layer was ultracentrifuged (45000 rpm, 2 hours, 4 ° C.) to obtain a precipitate. This precipitate was frozen and lyophilized. The obtained freeze-dried product was designated as periodontal disease bacteria LPS.

実施例３：脂肪酸部炭素数の異なる脂肪酸アミドプロピルベタインの歯周病菌及び大腸菌ＬＰＳに対する内毒素活性抑制効果
被験物質としてカプリル酸アミドプロピルベタイン（脂肪酸部炭素数８）、カプリン酸アミドプロピルベタイン（脂肪酸部炭素数１０）、ラウリン酸アミドプロピルベタイン（脂肪酸部炭素数１２）、ミリスチン酸アミドプロピルベタイン（脂肪酸部炭素数１４）、ヘキサデカン酸アミドプロピルベタイン（脂肪酸部炭素数１６）を用いた以外は実施例２と同様に試験して、歯周病菌及び大腸菌内毒素活性抑制試験を行った。測定結果を表３に示す。脂肪酸部炭素数が１４及び１６の場合に顕著な歯周病菌ＬＰＳ活性抑制効果が確認された。

Example 3: Inhibitory effect of endotoxin activity on periodontal disease bacteria and E. coli LPS of fatty acid amidopropyl betaines having different fatty acid part carbon numbers As test substances, caprylic acid amidopropyl betaine (fatty acid part carbon number 8), capric acid amidopropyl betaine (fatty acid) Part carbon number 10), lauric acid amidopropyl betaine (fatty acid part carbon number 12), myristic acid amidopropyl betaine (fatty acid part carbon number 14), hexadecanoic acid amidopropyl betaine (fatty acid part carbon number 16) The test was conducted in the same manner as in Example 2 to conduct a periodontal disease bacteria and E. coli endotoxin activity suppression test. Table 3 shows the measurement results. When the number of carbon atoms in the fatty acid part was 14 and 16, a remarkable periodontal pathogen LPS activity inhibitory effect was confirmed.

Claims (3)

An oral anti-periodontal fungus endotoxin agent comprising at least one fatty acid amidopropyl betaine having 8 to 16 carbon atoms in the acyl group portion derived from fatty acid as an active ingredient. The anti-periodontal disease endotoxin agent according to claim 1, wherein the fatty acid-derived acyl group portion of fatty acid amidopropyl betaine has 12 to 16 carbon atoms. The anti-periodontal disease endotoxin agent according to claim 1 or 2, comprising coconut oil fatty acid amidopropyl betaine as an active ingredient.